In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD. Nephron.Based on the information supplied: GFR category is:‡ Prediction of creatinine clearance from serum creatinine. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al.Indices of relative weight and adiposity. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL.A formula to estimate the approximate surface area if height and weight be known. Simplified calculation of body surface area. Agreement and Precision Analyses of Various Estimated Glomerular Filtration Rate Formulae in Cancer Patients. Chancharoenthana W, Wattanatorn S, Vadcharavivad S, Eiam-Ong S, Leelahavanichkul A.New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021 385(19):1737–1749 Inker L.A., Eneanya N.D., Coresh J., et al.KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Disease Improving Global Outcomes.International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) 2022.Calculated carboplatin doses are rounded to the nearest whole number.eGFR and BSA–adjusted eGFR are calculated to the nearest whole number.CrCl is calculated to two decimal places.BSA is calculated to two decimal places.Rounding is applied to the final result, no rounding is applied throughout the calculations. Note that target AUC may also be expressed as (mg mL -1 min)ĬrCl mL/minute (males) = (140 - age) x weight (kg) / 0.814 x serum creatinine (micromol/L), for females multiply result by 0.85 Note that BSA can be calculated using Mosteller or Dubois Dubois formulas.īSA (m 2) = 0.007184 x (height ) 0.725 x (weight ) 0.425īMI (kg/m 2) = actual weight (kg) / (height ) 2Ĭarboplatin dose (mg) = target AUC ( * minute) × See the ADDIKD guideline for further details.īody Surface Area (BSA) adjusted eGFR CKD-EPI equation 4īSA-adjusted eGFR CKD-EPI (mL/min) = / 1.73 However, to date, this adjustment has not been adopted by either Australian or international nephrology groups in the cancer setting. In 2021 the original equation was refitted without race (ie CKD-EPI 2021) 3. This is reflected in the ADDIKD guideline and utilised in eviQ. * The consensus recommendation is that Australian pathology laboratories use the CKD-EPI 2009 equation (without the race coefficient) when reporting eGFR (mL/min/1.73 m 2). that recalculation of carboplatin doses at each cycle is unnecessary except when baseline kidney function (i.e.kidney function should not be capped at 125 mL/min for use in the Calvert formula.avoiding the reduction of the initial target AUC in kidney dysfunction as it may compromise clinical benefit.The International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) 2022 1 recommends:.Creatinine clearance will be phased out of this calculator in the future. Creatinine clearance (CrCl) has been included as an option for kidney function in this calculator to support clinical practice in the transition to using BSA-adjusted eGFR in place of creatinine clearance.patient is neither an amputee, paraplegic or has conditions of skeletal muscle and is without extremes of body size or muscle mass.BSA-adjusted eGFR CKD-EPI may be suitable for use in the Calvert formula instead of mGFR where:.If using an estimated kidney function in the Calvert formula, the ADDIKD guideline recommends the use of BSA-adjusted eGFR CKD-EPI.Directly measured glomerular filtration rate (mGFR ) is the preferred kidney function value in the Calvert formula, especially where estimated kidney function may be unreliable for accurate therapeutic dosing.The calculator should only be used for patients older than 18 years.How you have radiation therapy treatment.How you have anticancer medicine treatment.Fertility, sex, pregnancy and breastfeeding.Complementary and alternative medicines.Gastric and oesophageal adjuvant and neoadjuvant.Genetic testing using cancer gene panels.Genetic testing for heritable pathogenic variants.

Creatinine clearance pcalc